It is scary to learn your child has neuroblastoma, a tumor of the peripheral nervous system that is the most common cancer in infants. It is scarier still when you get test results that show your child is in the half of neuroblastoma patients whose cancer is very aggressive and high-risk.
Pediatric oncology researchers at The Children’s Hospital of Philadelphia are driven to find new treatments for childhood cancer, and the Hyundai Hope On Wheels program is supporting their hard work by awarding a 2014 Scholar Hope grant to help fund investigations that focus on the aggressive form of neuroblastoma.
The Hogarty Laboratory studies the childhood tumor neuroblastoma. This enigmatic tumor is responsible for 15% of all childhood cancer deaths despite the use of highly intensive therapies, and survivors often suffer lifelong toxicities from their treatments. New approaches are needed to improve outcomes, and the lab seeks to understand the biology driving aggressive tumor behavior, and identify unique tumor-specific vulnerabilities.
Research in the Cole Lab focuses on identifying therapeutic vulnerabilities within molecularly defined subsets of pediatric central nervous system malignancies. The long-term goal of the lab is to identify effective therapies and improve the cure rate of children with malignant brain tumors.